{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:18:52Z","timestamp":1793999932186,"version":"4.8.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Investigation"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.resinv.2026.101431","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T02:52:14Z","timestamp":1776653534000},"page":"101431","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of erythromycin discontinuation owing to supply disruption on exacerbations in non-cystic fibrosis bronchiectasis: A retrospective cohort study"],"prefix":"10.1016","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6546-6376","authenticated-orcid":false,"given":"Takeshi","family":"Matsumoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Suga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Kajiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Matoba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Fujiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Kusakabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emi","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayuko","family":"Tashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikara","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9259-6256","authenticated-orcid":false,"given":"Kensaku","family":"Aihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.resinv.2026.101431_bib1","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S2213-2600(18)30053-5","article-title":"Bronchiectasis: new therapies and new perspectives","volume":"6","author":"Chalmers","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.resinv.2026.101431_bib2","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1183\/13993003.01033-2015","article-title":"Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study","volume":"47","author":"Quint","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2026.101431_bib3","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00051-2017","article-title":"Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research","volume":"49","author":"Hill","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2026.101431_bib4","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1164\/rccm.201711-2202OC","article-title":"Characterization of the \"Frequent Exacerbator Phenotype\" in bronchiectasis","volume":"197","author":"Chalmers","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2026.101431_bib5","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1001\/jama.2013.2290","article-title":"Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial","volume":"309","author":"Serisier","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.resinv.2026.101431_bib6","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1001\/jama.2013.1937","article-title":"Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial","volume":"309","author":"Altenburg","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.resinv.2026.101431_bib7","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1164\/ajrccm.157.6.9710075","article-title":"Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin","volume":"157","author":"Kudoh","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2026.101431_bib8","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0140-6736(12)60953-2","article-title":"Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial","volume":"380","author":"Wong","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.resinv.2026.101431_bib9","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.rmed.2014.09.005","article-title":"Long-term macrolide maintenance therapy in non-CF bronchiectasis: evidence and questions","volume":"108","author":"Haworth","year":"2014","journal-title":"Respir Med"},{"key":"10.1016\/j.resinv.2026.101431_bib10","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-2600(19)30191-2","article-title":"Long-term macrolide antibiotics for the treatment of bronchiectasis in adults: an individual participant data meta-analysis","volume":"7","author":"Chalmers","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.resinv.2026.101431_bib11","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00629-2017","article-title":"European Respiratory Society guidelines for the management of adult bronchiectasis","volume":"50","author":"Polverino","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2026.101431_bib12","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/resp.14479","article-title":"Thoracic Society of Australia and New Zealand (TSANZ) position statement on chronic suppurative lung disease and bronchiectasis in children, adolescents and adults in Australia and New Zealand","volume":"28","author":"Chang","year":"2023","journal-title":"Respirology"},{"key":"10.1016\/j.resinv.2026.101431_bib13","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.resinv.2024.09.004","article-title":"Efficacy and safety of long-term macrolide therapy for non-cystic fibrosis bronchiectasis: a systematic review and meta-analysis","volume":"62","author":"Nakagawa","year":"2024","journal-title":"Respir Investig"},{"key":"10.1016\/j.resinv.2026.101431_bib14","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jiac.2017.12.008","article-title":"The association between erythromycin monotherapy for Mycobacterium avium complex lung disease and cross-resistance to clarithromycin: a retrospective case-series study","volume":"24","author":"Hosono","year":"2018","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.resinv.2026.101431_bib17","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12931-021-01729-5","article-title":"Risk factors for Pseudomonas aeruginosa colonization in non-cystic fibrosis bronchiectasis and clinical implications","volume":"22","author":"Kwok","year":"2021","journal-title":"Respir Res"},{"key":"10.1016\/j.resinv.2026.101431_bib18","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12890-024-02888-z","article-title":"High-sensitivity C-reactive protein level in stable-state bronchiectasis predicts exacerbation risk","volume":"24","author":"Kwok","year":"2024","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.resinv.2026.101431_bib19","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/S2213-2600(25)00160-2","article-title":"Symptoms, risk of future exacerbations, and response to long-term macrolide treatment in bronchiectasis: an observational study","volume":"13","author":"Sibila","year":"2025","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.resinv.2026.101431_bib20","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1136\/thoraxjnl-2019-213929","article-title":"British Thoracic Society guideline for the use of long-term macrolides in adults with respiratory disease","volume":"75","author":"Smith","year":"2020","journal-title":"Thorax"},{"key":"10.1016\/j.resinv.2026.101431_bib21","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00228-011-1161-x","article-title":"Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases","volume":"68","author":"Zarogoulidis","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.resinv.2026.101431_bib22","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1164\/rccm.200212-1437OC","article-title":"In vivo and in vitro effects of macrolide antibiotics on mucus secretion in airway epithelial cells","volume":"168","author":"Shimizu","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2026.101431_bib23","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1128\/CMR.00078-09","article-title":"Mechanisms of action and clinical application of macrolides as immunomodulatory medications","volume":"23","author":"Kanoh","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.resinv.2026.101431_bib24","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S2213-2600(13)70038-9","article-title":"Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases","volume":"1","author":"Serisier","year":"2013","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.resinv.2026.101431_bib25","first-page":"Cd012406","article-title":"Macrolide antibiotics for bronchiectasis","volume":"3","author":"Kelly","year":"2018","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Respiratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534526000651?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534526000651?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T12:58:49Z","timestamp":1778849929000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212534526000651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2212534526000651"],"URL":"https:\/\/doi.org\/10.1016\/j.resinv.2026.101431","relation":{},"ISSN":["2212-5345"],"issn-type":[{"value":"2212-5345","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of erythromycin discontinuation owing to supply disruption on exacerbations in non-cystic fibrosis bronchiectasis: A retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Respiratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resinv.2026.101431","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Japanese Respiratory Society. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101431"}}